Plasma membrane endothelin type A (ET A) receptors are internalized and recycled to the plasma membrane, whereas endothelin type B (ET B) receptors undergo degradation and subsequent nuclear translocation. Recent studies show that G protein-coupled receptors (GPCRs) and ion transporters are also present and functional at the nuclear membranes of many cell types. Similarly to other GPCRs, ET A and ETB are present at both the plasma and nuclear membranes of several cardiovascular cell types, including human cardiac, vascular smooth muscle, endocardial endothelial, and vascular endothelial cells. The distribution and density of ET ARs in the cytosol (including the cell membrane) and the nucleus (including the nuclear membranes) differ between these cell types. However, the localization and density of ET-1 and ET B receptors are similar in these cell types. The extracellular ET-1-induced increase in cytosolic ([Ca] However, the cytosolic ET-1-induced increase of [Ca] n does not depend on cell type. In conclusion, nuclear membranes' ET-1 receptors may play an important role in overall ET-1 action. These nuclear membrane ET-1 receptors could be targets for a new generation of antagonists.
IN THE LAST TWENTY YEARS, most studies addressing the role of endothelin-1 (ET-1) on modulation of heart and vascular smooth muscle (VSM) functions have focused on sarcolemma endothelin type A (ET A Rs) and endothelin type B (ET B Rs) receptors. Among those studies, several were directed toward ET-1 modulation of cytosolic Ca 2ϩ during excitation-contraction coupling in conditions of health and disease. However, growing evidence in the literature raises new paradigms related to a cross talk between cytosolic and nuclear Ca 2ϩ (1, 2, 4, 10 -26, 34, 42, 43, 45, 50, 57, 63, 68, 71, 74, 75 ; for review, see Refs. 11, 22, 25, 29) and the presence of G protein(s)-coupled receptors at the nuclear envelope membranes (8, 10 -23, 25, 26, 30, 42, 55, 57, 68, 71, 74 ; for review, see Refs. 11 and 13), such as ET-1 receptors (10 -15, 19 -22, 24, 25, 28, 49, 51, 56, 57, 68, 71) . Stimulation of nuclear membrane receptors contributes to nuclear signaling processes, including nuclear free Ca 2ϩ level (1-3, 8, 10 -26, 29, 31, 42, 49, 56, 57, 68, 71, 74) , cell cycle, gene expression (36, 47, 55, 74) , activation of nuclear kinases (73) and phosphateases, as well as DNA repair, break down of the nuclear envelope, and apoptosis (70; for review, see Refs. 11, 22, 29, 36, 47) . Studies using isolated nuclear membrane vesicles did not take into consideration the cross talk that may exist between the nuclear membrane nuclear receptors and ion transporters on one hand, and the surrounding cytosolic environment of the living cell on the other hand (30) . It was not until the development of ionic fluorescent probes, mainly Ca 2ϩ probes, and real three-dimensional (3D) confocal microscopy techniques, that several laboratories, including ours, rediscovered the nucleus as a cell within a cell (3, 10 -26, 35, 36, 44, 47, 51, 56, 68, 80) . Furthermore, the nucleus possesses nuclear structures (11, 12, 25, 41, 47, 64) that may largely participate in ET-1 regulation of life and death of the cell (70) . Thus the use of real 3D confocal microscopy imaging in living cells allowed several laboratories, including ours, to visualize and quantify cytosolic and nuclear ET-1 and ET-1 receptor trafficking along with nuclear Ca 2ϩ movements and signaling (3, 10 -15, 19 -22, 24, 25, 28, 56, 57, 68, 71) .
In the present review, we emphasize the contribution of ET-1 and ET-1 nuclear membrane receptors to overall cytosolic and nuclear signaling. We show that plasma membrane ET-1 receptor-mediated cytosolic signaling is transferred to the nucleus through the nuclear pore and/or via the signaling of nuclear membrane ET-1 receptors.
Critical Technical Issues of Fluorescence Real 3D Imaging of Cytosolic and Nuclear ET-1 Receptors
The development and use of real 3D confocal microscopy coupled to high-performance hardware and software systems has provided scientists with the capacity to overcome some of the limitations of standard microscopy imaging measurements and image deconvolution (19, 20) . However, to optimize this technique, one should be familiar with the basic approaches and limitations of confocal microscopy. For further information on the latter topic, the reader is invited to refer to key studies (11, 19, 20, 22, 25) .
To overcome the limitation of using fluorescence imaging for the detection of ET-1 receptors and measurement of Ca 2ϩ signals in the cytosol and nucleus, the following should be considered: 1) cell phenotypes should be stable, and those cells should be plated at low density and well attached to a glass cover slip; 2) laser line intensity, photometric gain, photomultiplier tube settings, and filter attenuation should be set below the autofluorescence level of the cell and these settings kept rigorously constant throughout all of the experiments; 3) for ionic probes, optimal loading should be ensured by determining the relative concentration of the bound and nonbound probe; 4) for ET-1 and ET-1 receptor fluorescence density measurement, specificity and selectivity of the antibody should be ensured using different controls, such as blocking peptides, deletion of the receptors' genes (small-interfering or shorthairpin RNA), as well as ensuring that Western blot reveals only the band corresponding to the target protein; 5) in simultaneous double, triple, or quadruple labeling, absence of cross reaction between the different antibodies used should be ensured; 6) for real 3D imaging, the cell should be quiescent; 7) in studying nuclear transport of macromolecules, as well as nuclear internalization and de novo synthesis of receptors, the extranuclear milieu should not contain any cell debris; 8) access to the nuclear membrane receptors and channels should be gained by either extracting the nucleus or by perforating the sarco- Fig. 1 . Presence and distribution of endothelin type A (ETAR) and endothelin type B (ETBR) receptors in cardiovascular cells. A: 3-dimensional (3D) reconstruction top-view image of a cardiomyocyte labeled with a fluorescent probe coupled to endothelin-1 (ET-1). The fluorescence is spread from the plasma membrane to the cytosol and the nucleus (white arrow indicates the nucleus). B: a cardiomyocyte labeled with fluorescent probe tagged to ET-1, presented in a "look-through" mode with a cross-sectional cut at the top. The figure demonstrates that the fluorescence is not limited to the plasma membrane. C-E: double labeling of a human vascular smooth muscle cell with anti-ETA and anti-ETB antibodies. The receptors' fluorescence is presented in the surface-plot mode, with a Ϫ4°tilt. ETA is present at the plasma membrane, the cytosol, and the nuclear membranes (C). However, it is absent in the nucleoplasm. ETBR is found throughout the cell (sarcolemma membrane and cytosol), including the nucleus (nuclear envelope membranes and nucleoplasm). The merge of ETAR and ETBR fluorescence in E demonstrates colocalization of the fluorescence of the two receptors at the sarcolemma membrane and absence of colocalization in the nucleus. The pseudocolor scale represents fluorescence intensity according to an arbitrary scale from 0 nm (black, absence of fluorescence) to 255 nm (white, maximum fluorescence). The scale of the white bar is in m (modified from Refs. 14 and 22). lemma membrane (1, 12, 15, 20, 21, 26) ; 9) a minimum of 36 serial sections, and optimal 75-150 serial sections of the cell (depending on the morphology), should be taken for real 3D imaging; and 10) transiently occurring phenomena should be only monitored and subsequently disclosed using "rapid scan" of a cell section. This will permit measuring temporal changes of density and redistribution. Measurement of amplitude of the temporal changes of contracting cells is not possible because of continuous change of the position of the cell section; 11) small, fast, and instantaneously occurring changes in kinetics of cytosolic and nuclear events should be recorded using the "line scan" technique, which exclusively measures temporal changes; 12) temporal changes, including Ca 2ϩ changes during cell contraction, can be measured using rapid scan; 13) for measurement of cytosolic and nuclear fluorescence intensities, at the end of the experiment, labeling of the nucleoplasm should be done using nuclear probes, such as Syto-11; 14) because of variations in volumes between cells or between intracellular organelles, the fluorescence intensity should be normalized and expressed per cubic micrometer; 15) measurement in a single section of a cell represents fluorescence intensity of a surface area that should be expressed per square micrometer and not represent the absolute level of fluorescence intensity of the whole cell; and 16) it is recommended to determine the distribution of the fluorescent probe when a new type of cell is used. Fluo 3 as well as other Ca 2ϩ probes such as indo 1, fluo 4, Ca 2ϩ green, yellow cameleon, and fura 2 are equally distributed in the cytosol and the nucleus of cardiomyocytes, vascular smooth muscle cells (VSMCs), vascular endothelial cells (VECs), and endocardial endothelial cells (EECs) of human (h), rat, rabbit, hamster, and mouse origins (14, 25) . These fluorescent probes can be used safely in these previously mentioned cell types.
All of these above-described aspects, in addition to others (for details, see Refs. 19 and 20) , should be established and well controlled throughout the experiment to accurately determine the fluorescence distribution and density of a fluorescent probe.
Nuclear Localization of ET-1 System Components in Human Cardiomyocytes, hEECs, hVSMCs, and hVECs
Short-term exposure of human or chick single heart cells to extracellular ET-1 fluorescent probe (25) revealed the presence of ET-1 receptors in the plasma membrane in a cluster-like fashion (Fig. 1A) . However, longer exposure of the same single cell to the extracellular ET-1 fluorescent probe also showed labeling in the cytosol as well as at the nuclear envelope membranes. Figure 1B shows an example of a "look-through" real 3D fluorescence image (25) . Presence of the fluorescent probe at the cytosolic level indicates that the receptor at the plasma membrane was internalized along with its fluorescent ligand (25) . Furthermore, presence of fluorescent labeling at the nuclear membrane levels teaches us that the fluorescent ET-1, internalized along with its receptors, binds to ET-1 receptors of the nuclear membranes (11, 25) . Washout of the extracellular ET-1 fluorescent probe did not remove the labeling of ET-1 receptors. However, pretreatment with nonlabeled ET-1 prevented labeling of ET-1 receptors by the ET-1 fluorescent probe (14, 25) . Cytosolic application of the ET-1 fluorescent probe showed labeling of ET-1 receptors at the nuclear envelope membranes (21) . This clearly suggests that extracellular ET-1 is internalized along with its receptors, and it is made available to bind to its receptors in the nuclear envelope membranes.
Antibodies directed toward ET A R and ET B R revealed the presence of the latter proteins at the plasma membrane, cytosol, nuclear envelope membranes, as well as at the nucleoplasm of hVSMCs (Fig. 1, C-E) , human cardiomyocytes, hEECs, and hVECs (11, 14, 22, 25, 57) . Figure 1 , C-E, shows examples of a surface plot of fluorescent double labeling of ET A R and ET B R in hVSMCs, whereas Fig. 2 quantifies the results (11, 14, 22, 57) . The ET A R density is higher in the cytosol and in the cell membrane than in the nucleus (including the nuclear membranes) in hVSMCs and hEECs (11, 14, 22, 57) . However, in hVECs, the density of ET A Rs is higher in the nucleus than in the cytosol ( Fig. 2A) (6) . These results show that ET A R is also present at the nuclear level; however, its density depends on the cell type. In contrast to ET A R, ET B R density is higher in the nucleus than in the cytosol of all human cell types tested (Figs. 1D and 2B) (6, 11, 14, 22, 52) .
The order of density of nuclear ET A Rs in the different cardiovascular cells is: hVEC Ͼ hVSMCs Ͼ hEECs, whereas, for nuclear ET B , it is: hVEC Ͼ hEEC Ͼ hVSMCs (6, 11, 14, 22, 57) . However, the orders of density of ET A R and ET B R in the cytosol (including the cell membrane) are, respectively: hVEC ϭ hVSMC Ͼ hEEC and hVSMC ϭ hEECs Ͼ hVEC (6, 11, 14, 22, 57) . Thus the density of ET A R or ET B R at the cell membrane plus cytosol is similar in different cell types of the same species. However, we cannot make such a generalized conclusion for nuclear ET-1 receptors. Hence, it is postulated that the cell-type-dependent effect of ET-1 is due, at least partly, to the differences in nuclear ET-1 receptor densities of different cell types.
Similar to intact cell, isolated nuclei of hVSMCs (11, 22) also showed the presence of nuclear membrane ET B Rs at the outer and inner nuclear membranes (Fig. 3, A and B) in a cluster-like fashion. Furthermore, these receptors are also present within the nucleus (Fig. 3C ), possibly at both the nucleoplasm (11) and nuclear T tubule (NTTs) membrane levels (5, 11, 41) . Because NTTs are distributed throughout the nucleoplasm (5), the ET B Rs present at the NTT membranes may contribute to acceleration of propagation of signaling of these receptors deeper within the nucleoplasm (5, 41) . Although the presence of ET-1 at the level of the cytosol is expected, the presence of the ligand in the nucleoplasm is also sought (Fig. 4) (11, 22) , since it can be made available for its receptors present at the membranes of both the nuclear envelope (11, 22, 25) and NTTs (5, 11, 41) . Surprisingly, the density of ET-1 is higher in the nucleus than in the cytosol of both ET-1-secreting cells, hVECs and hEECs ( 
Transcellular Trafficking of ET-1 and Its Receptors
In addition to its conventional cytoplasmic membrane localization, the endothelin-converting enzyme-1a is also targeted to the nuclear membrane (58) . Furthermore, receptors such as ET B present in the nucleoplasm (Figs. 2 and 3) (6, 11, 22) could be targeted to nuclear membranes. Thus nuclear membrane receptors may originate from the nucleoplasm (Fig. 5 ) (55) . The activation of these nuclear membrane ET-1 receptors by their respective cytosolic or perinucleoplasmatic ligands would cause nuclear second messenger formation, such as inositol trisphosphate (IP 3 ) (59, 63) and PKC activation (73) . These ET-1 receptor activation products may directly regulate nuclear membrane ionic transporters (11, 42, 53, 80) as well as nuclear pore complex trafficking of macromolecules (34) . The schematic model in Fig. 5 suggests that internalization of ET-1 with its receptors ET A and ET B (Fig. 5, A-F) will lead the ET-1/ET A R and ET-1/ET B R complexes to recycling and degradation, respectively (9, 11, 51) . Both phenomena would release ET-1 in the cytosol (9, 11, 16, 22, 51) and make it available for activation of nuclear membrane ET-1 receptors. Hence cytosolic free ET-1 can activate outer nuclear membrane ET B Rs, as was reported in cardiomyocytes using ET-1 fluorescent probe (21, 22, 25) . We also hypothesize that, during increases of cytosolic Ca 2ϩ , cytosolic ET-1, normally present in secretory vesicles (Fig. 5, in yellow) , is simultaneously released extracellularily and in the nuclear envelope space via the same exocytosis process (31) . The ET-1 released in the perinucleoplasm will be available for activation of the inner nuclear membrane ET B Rs (Fig. 5) (11, 14, 25) . If we consider that the nucleus is a cell within a cell (11, 22) and because ET-1 is also present in the nucleoplasm, this process may also take place from the nucleoplasm toward the nuclear envelope space (Fig. 5) . According to this hypothesis, the increase of nucleoplasmic free Ca 2ϩ would promote exocytosis (exonucleosis) of nucleoplasmic ET-1 to the perinucleoplasm, which in turn activates ET-1 receptors located at the inner nuclear membrane (Fig. 5) . We do not exclude that the increase of perinucleoplasmic free Ca 2ϩ will promote exocytosis (exoperinucleosis) of perinucleoplasmic ET-1 and liberation of this peptide in the cytosol, thus activating ET-1 receptors located at the outer nuclear membrane (Fig. 5) . Activation of these nuclear membrane receptors would further promote transnuclear membrane Ca 2ϩ influx and release of nucleoplasmic Ca 2ϩ via nuclear ryanodine receptor and IP 3 receptor pools (12, 59, 64, 80) . Thus it is possible that activation of nuclear membrane ET-1 receptors may follow the activation of plasma membrane ET-1 receptors. In addition, nuclear membrane ET-1 receptors could be activated by its ligand(s) locally released from the nucleus, independent of plasma membrane ET-1 receptor activation (Fig. 5) . The increase of nucleoplasmic ET B R density following activation of plasma membrane ET B Rs (Fig. 5 ) could be in part due to both nuclear translocation (11) and/or nuclear mobilization and/or de novo nuclear synthesis of the receptor (Fig. 5) (11, 55) . Thus the density of a particular type of ET-1 receptor is not identical in plasma and nuclear membranes, and the nuclear membranes may possess a higher density for one particular subtype of a given receptor relative to plasma membrane ( Fig. 2) (6, 11, 22) . Because ET-1 receptors exist at both the nuclear membranes and the cell membranes, we postulate that a cross talk exists between cell membrane receptors and nuclear membrane receptors of the same cell (Fig. 5) . Such a cross talk may imply that nuclear ET-1 receptors also play a role of relay for their receptors present at the cell membrane, thus perpetuating their signaling to the nucleoplasm.
In conclusion, our recent results and ongoing work strongly support the hypothesis that many biochemical events occurring at the plasma membrane and cytosolic levels also occur in a parallel manner at the nuclear membranes and within the nucleus. Such nuclear events may occur dependently and independently of those occurring at plasma membrane and cytoplasmic levels (Fig. 5) .
Extracellular ET-1 Modulation of Cytosolic and Nuclear Free Ca 2ϩ Signaling
In hVSMCs, hVECs, and cardiomyocytes, increasing the concentration of extracellular ET-1 from 10 Ϫ17 up to 10 Ϫ5 M induced a dose-dependent increase of both sustained basal cytosolic free Ca 2ϩ ([Ca] c ) and nuclear free Ca 2ϩ ([Ca] n ). Figure 6 shows a compilation of different published results (6, 11, 13, 21, 24, 57 (Fig. 6) . Moreover, the increase of nuclear Ca 2ϩ by extracellular ET-1 seems to be mainly, but not exclusively, the result of the stimulation of Ca 2ϩ influx through the sarcolemma membrane (21, 25, 57) .
The type of receptor mediating the ET-1-induced increase of [Ca] c and [Ca] n depends on the cell type (6, 11, 12, 21, 56, 57) . (Fig. 7, A-H) . Similar results were reported in cardiomyocytes and left ventricular hEECs (12, 21, 57) . However, in hVECs and right ventricular hEECs, only the ET A R is responsible for the ET-1-induced increase of [Ca] c and [Ca] n (6, 56). Thus it is not possible to make a generalization in relation to the type of ET-1 receptor responsible for the modulation of cytosolic and nuclear Ca 2ϩ . In isolated nuclei of hVSMCs, ET-1 (10 Ϫ11 M) induced an increase of [Ca] n (Fig. 8A) . Furthermore, extranuclear ET B R agonist IRL-1620 induced an increase of [Ca] n (Fig. 8B) . In cardiomyocytes and hVSMCs, cytosolic ET-1 as low as 10
Ϫ15
M induced a sustained increase in [Ca] n (Fig. 9) . A steady-state effect takes place in heart cells at 10 Ϫ10 M, whereas, in hVSMCs, it is only reached at a concentration of 10 Ϫ6 M (Fig.  9) . Accordingly, the EC 50 of cytosolic ET-1 on [Ca] n is lower in cardiomyocytes (Ϯ10 Ϫ14 M) than that in hVSMC nuclei (Ϯ10 Ϫ11 M). Furthermore, the EC 50 of cytosolic ET-1 on [Ca] n of both cardiomyocytes and hVSMCs was lower than that of extracellular ET-1. These results demonstrate that nuclear membrane ET-1R has intrinsically higher affinity to cytosolic ET-1 than to those located at the cell membrane. The difference between the EC 50 of extracellular and cytosolic ET-1 could be partly due to differences of composition between the cell and nuclear membranes, which may permit a better interaction of ET-1 with its receptor. Alternatively, there could be a different endogenous agonist that stimulates these nuclear membrane receptors, and/or the nuclear receptors and their pharmacology are different than those of the cell membrane. Because the nuclear envelope receptors are more sensitive to ET-1 than those present at the sarcolemma membrane, we postulate that ET-1 internalized with its plasma membrane receptor could be snatched by the nuclear membrane ET-1 receptors (14) , thus activating the latter. All of these aspects should be further investigated in the future.
In both intact cells and isolated nuclei (11, 12, 14) , the effect of ET-1 on [Ca] c and [Ca] n was completely blocked by the Ca 2ϩ chelator EGTA (13) . In intact cells, the ET-1 increase of [Ca] c is due to an increase of Ca 2ϩ influx through the sarcolemma membrane, whereas the increase of [Ca] n is at least in part due to cytosolic Ca 2ϩ buffering by the nucleus (12, 21, 22, 25, 57). However, in isolated nuclei, the increase in [Ca] n by cytosolic ET-1 is not exclusively the result of the stimulation of 
Ca
2ϩ influx through nuclear envelope membranes (11, 13, 57, 68) . In fact, in isolated nuclei, in absence of cytosolic Ca 2ϩ , cytosolic ET-1 induced an increase in [Ca] n (25) . Therefore, stimulation of ET-1 receptors of the nuclear envelope membranes induced both nuclear Ca 2ϩ influx (11, 13, 25) and mobilization of nucleoplasmic Ca 2ϩ (25) .
Cytoplasmic ET-1 Modulation of Ca 2ϩ Buffering Capacity of the Nucleus in Cardiomyocytes and VSMCs
Extracellular and cytosolic ET-1 induced a steady-state increase in [Ca] 
ET-1 and Cytosolic and Nuclear Reactive Oxygen Species Generation
It is well established that the major products of superoxide metabolism, such as hydrogen peroxide (H 2 O 2 ), have multiple actions on cell function (38, 44, 61, 77, 78) . Compelling evidence shows that extracellular ET-1 induces NADPH oxidase to stimulate production of superoxide from several cell types (38, 77) . Over the past few years, growing evidence has implicated both ET-1 and cytosolic reactive oxygen species (ROS) as pathological mediators of cardiovascular diseases (38, 61, 77, 78) . However, little attention has been given to the nucleus.
Similar to H 2 O 2 , extracellular ET-1 (10 Ϫ9 M) induced a sustained increase of both cytosolic and nuclear ROS (71) in hEECs (Fig. 10, A-E) (71) and hVSMCs (71) . In the presence of ET-1, superfusion with glutathione (10 mM) reversed the ET-1-induced sustained increase of cytosolic and nuclear ROS in both cell types (Fig. 10, A-C and E) (71) . In addition, the resting basal level of ROS in the nucleus of both hEECs and hVSMCs is higher than in the cytosol (71) . This again demonstrates that, like Ca 2ϩ and Na ϩ (11, 14) , in resting as well as stimulated states, ROS have a higher density in the nucleus than in the cytosol (71) . Hence, ET-1 was found to induce an increase of both ROS and Ca 2ϩ in both the cytosol and the nucleus of all cells tested, including hEECs and hVSMCs (25, 71) .
Extranuclear ET-1 (10 Ϫ11 M) induced a sustained increase in nuclear ROS (Fig. 10F) (71) . In the presence of cytosolic (extranuclear) ET-1, addition of H 2 O 2 (50 M) to the extranuclear milieu did not further increase the level of nuclear ROS (71) . However, the increase of nuclear ROS by cytosolic ET-1 (in the presence of H 2 O 2 ) was reversed by glutathione (10 mM) (Fig. 10F) . Thus ROS levels in the nucleus can be increased by cytosolic ET-1, and further increase of cytosolic H 2 O 2 does not amplify the cytosolic ET-1 response. This suggests that the cytosolic ET-1-induced increase of nuclear ROS can be mediated via the H 2 O 2 pathway (71). Furthermore, cytosolic H 2 O 2 (50 M) induces a sustained increase of nuclear ROS, whereas cytosolic ET-1 (10 Ϫ11 M) does not further raise the H 2 O 2 -induced increase of ROS (71) . The increase of ROS by H 2 O 2 or by ET-1 is reversed with glutathione (71) . Thus the nucleus can generate its own ROS, and nuclear ET-1 receptor activation contributes directly to nuclear ROS generation.
Role of Nuclear ET-1 Receptors in Physiology and Pathophysiology
ET-1 is also known as a cardiac hypertrophic factor (39) . Because, as in cell membranes, functional ET-1 receptors are also present at the nuclear membranes of all types of cells tested, and because the density of ET B Rs is higher in the nucleus than in the cell membrane and the cytosol (31), we thus postulate that the ET-1-induced hypertrophy is not only cytoplasmic but nuclear as well. Such a phenomenon seems to exist in human cardiomyocytes as shown, for example, in Fig. 11 . As seen in Fig. 11, treatment with 10 Ϫ7 M ET-1 for 48 h induced an increase of both cytosolic and nuclear volumes of these cell types (Fig. 11) . These results clearly demonstrate that the ET-1-induced hypertrophy takes place also at the nuclear level. Furthermore, these results showed that ET-1 is not only a cardiomyocyte hypertrophic factor, but it also induces nuclear hypertrophy. Nuclear ET-1 receptor activation and generation of nuclear ROS may also contribute to the ET-1-induced generation of ROS in cardiovascular pathology.
The activation of nuclear membrane ET-1 receptors and the resulting increase of nuclear Ca 2ϩ shield the nucleus from cytosolic Ca 2ϩ overload that characterizes several cardiovascular pathologies, such as reperfusion-induced increase of intracellular Ca 2ϩ , hypertension, and hypoxia.
Discussion
In conclusion, our results as well as those of others reported in the literature clearly demonstrate that ET-1 receptors are present at both the plasma membrane and nuclear envelope membranes. These receptors may contribute to maintaining not only Ca 2ϩ influx through the plasma membrane but also participate in controlling the basal nucleoplasmic free Ca 2ϩ in resting cells (11, 14, 22, 25) . As shown in the literature as well as in our published work (10 -26, 57, 68, 71) , several highly active circulating compounds, such as ET-1, may directly act at the nuclear envelope membrane level. Consequently, this would promote both Ca 2ϩ entry in the nucleus as well as nucleoplasmic Ca 2ϩ release, thus increasing [Ca] n and shielding the nucleoplasm from sustained nucleoplasmic Ca 2ϩ overload (11, 25) . Thus, ET-1 receptor-mediated Ca 2ϩ signals are not only limited to the cytoplasm but also take place in the nucleus via nuclear uptake of cytosolic Ca 2ϩ (16, 21, 25) and/or via ET-1-stimulated IP 3-induced nucleoplasmic Ca 2ϩ release (5, 49, 79) . Alternatively, this phenomenon may also take place independent of cytosolic Ca 2ϩ and IP 3 changes, by direct activation of nuclear ET-1 receptors by ET-1 present in the cytosol (11, 13, 14, 16) . Thus changes in extracellular and/or intracellular and/or nucleoplasmic levels of ET-1 as well as changes in cell membrane and/or nuclear membrane ET-1 receptor density would either indirectly or directly affect nuclear Ca 2ϩ signaling. In addition to the cytosolic Ca 2ϩ -buffering property of the nucleus (16, 25) and its regulation by ET-1 receptor stimulation (25) (65, 69, 72, 76) and nuclear Ca 2ϩ -binding proteins (such as calmodulin and calpains) (7, 60) that are known to regulate both cell function and gene expression (46) . Current knowledge dealing with plasma membrane ET-1 receptors teaches us that the presence of either ET A R or ET B R is cell type dependent (26, 32, 37) . However, recent work investigating nuclear membrane ET-1 receptors shows that the presence of a certain type of ET-1 receptor in a cell is not determined only by its presence in the cell membrane but also by its presence in the nuclear membranes. The presence of ET A Rs in two types of endothelial cells, the hVECs and hEECs, demonstrates that at least human endothelial cells possess ET A Rs and that ET B Rs are not the only type of ET-1 receptor present in these types of cells (6, 57) . The role of ET B Rs as ET-1 clearance receptor is well documented in the literature (9, 32) , whereas the role of ET A Rs seems to be related to modulation of intracellular Ca 2ϩ (6) . Whether nuclear membrane ET A R and ET B R play other roles in regulating cell function remains to be elucidated. It is nonetheless possible to postulate that the ET A R, which seems to be highly present at the nuclear level of endothelial cells, may contribute to the secretion process via regulating [Ca] c and [Ca] n homeostasis (6, 57) . The presence of this type of receptor on the nuclei of both hEECs (6, 57) and hVSMCs (11) as well as Fig. 12 . Schematic representation of various components present in both a cell and its nucleus that directly or indirectly modulate both cytosolic and nuclear Ca 2ϩ . TT, T tubule; NTT, nuclear T tubule; NR, nucleoplasmic reticulum; RyR, ryanodine receptor; IP3R, inositol trisphosphate (IP3) receptor; ER, endoplasmic reticulum; SR, sarcoplasmic reticulum; R, ET-1 receptor; NO, nitric oxide; NOX, NADPH oxidase; PKG, protein kinase G; sGC, soluble guanylate cyclase; puffs, IP3-generated Ca 2ϩ wave; spark, RyR-generated Ca 2ϩ wave (modified from Ref. 11). cardiomyocytes (27) significantly highlights its importance as a target for drug action. The presence of a high density of ET B Rs in the nuclear membranes of cardiomyocytes, hVSMCs, hVECs, and hEECs (11) strongly suggests that this type of receptor may also contribute to the modulation of nuclear Ca 2ϩ as well as survival and/or hypertrophy and/or cell cycle and/or gene expression. The presence of ET-1 at the nuclear level supports our concept that, wherever the receptor is present, its ligand will be present (Fig. 5 and Ref. 23 ). Our hypothesis is that, similar to the signaling of plasma membrane ET-1 receptors, the nuclear membrane ET-1 receptor activation would induce similar signaling in the nucleus, including PKC activation and IP 3 formation. As in the case of cytosolic IP 3 -induced endoplasmic reticulum/sarcoplasmic reticulum Ca 2ϩ release (49, 79) and cytosolic PKC-induced cytoskeleton reorganization (66, 67) , the nucleoplasmic IP 3 would contribute to release of Ca 2ϩ from a nucleoplasmic reticulum (Fig. 12 ), whereas nuclear PKC activation would contribute to modulation of the nucleoskeleton (nuclear skeleton). The latter also has been reported to modulate ET-1 gene expression (66) . Furthermore, ET A R blockade was reported to inhibit remodeling of the cytoskeleton (67) . The specific PKC isoforms present in the nucleus seem to be of ␣ (33), ␦, €, and (73) types. The localization of these PKC isoforms in the cell nucleus strongly indicates that these isoforms, which can be regulated by nuclear membrane ET-1 receptor activation, are directly involved in the regulation of nuclear processes (73) , including RNA transcription, processing, and export. The nuclear ET-1 receptor modulation of the nucleoskeleton would also modulate chromatin-remodeling complexes (66, 67) . The contribution of nuclear membrane ET-1 receptors to nuclear nucleoskeleton organization remains to be elucidated.
Cell hypertrophy is not necessarily accompanied by an increase of nuclear volume (G. Bkaily and D. Jacques, unpublished observation). However, ET-1-induced hypertrophy contributes to remodeling of both whole cell (54, 62) and nuclear volumes. Whether this increase of nuclear volume by extracellular ET-1 is partially a consequence of remodeling of nucleoskeleton and/or NTTs induced by activation of nuclear membranes' ET-1 receptors remains to be verified. In type I diabetes, both cytosolic and nuclear Ca 2ϩ decreased to the same level in VSMCs (75) by modulating the density of nuclear membrane receptors. Enhanced generation and accumulation of ROS by ET-1 reported in several cardiovascular pathologies (44, 77, 78 ) is transmitted to the nucleus (71) . Similar to Ca 2ϩ (13, 14) , an increase of cytosolic ROS is transmitted to the nucleus, which is also able to generate its own ROS via nuclear membrane ET-1 receptor activation (71) . The nuclear membrane ET-1 receptor generation of nuclear ROS would contribute to modulation of nuclear Ca 2ϩ homeostasis as well as nucleoskeleton reorganization and nuclear hypertrophy. These latter phenomena should be verified in the future.
In normal conditions and in all normal healthy cells tested, a difference exists between the level of cytosolic and nuclear Ca 2ϩ , and this is independent of the Ca 2ϩ probe used (11, 22, 24, 25) . Furthermore, the nuclear pore does not contribute directly to Ca 2ϩ transport in either direction, since its blockade does not affect the resting nuclear Ca 2ϩ level (G. Bkaily and D. Jacques, unpublished observation). The difference between cytosolic and nuclear Ca 2ϩ is regulated and maintained by nuclear receptors and ionic transporters similar to those present in the plasma membrane (11, 14, 22, 25) . Such a difference between cytosolic and nuclear Ca 2ϩ levels becomes more apparent in highly active and stimulated cells (25) as reported in some diseases, such as hypertrophy. In some specific conditions that mimic cardiovascular dysfunctions, such as overexpression of the cell membrane and nuclear membranes, ANG II type 1 receptors (26) , and in cardiomyopathy (G. Bkaily and D. Jacques, unpublished observation), there is no difference between [Ca] c and [Ca] n . In conclusion, endothelin regulation of cell function cannot anymore be attributed only to activation of plasma membrane ET-1 receptors and their downstream signaling but also to activation of nuclear membrane ET-1 receptors and their nuclear signaling.
Perspectives and Significance
The presence of functional ET-1 receptors at the nuclear membranes opens a new perspective in the field of endothelin. This new area of ET-1 research will help us to better understand the complex mechanisms underlying the role of ET-1 in cell function. There is no doubt that several aspects remain to be elucidated on the roles of each type of nuclear membrane ET-1 receptor and their contribution to overall ET-1 action in health and diseases. The growing evidence regarding the role of nuclear membrane ET-1 receptors will allow the optimal identification of new targets toward the development of specific nuclear membrane ET-1 receptor antagonists that act specifically on overstimulation of the nuclear membrane ET-1 receptors. Further studies should, however, be performed in this new field of nuclear membranes' G protein-coupled receptors, and specifically those involved in ET-1-induced cellular events.
